FGFR a promising druggable target in cancer: Molecular biology and new drugs

Pablo Reclusa Asiain, Tindara Franchina, Rut Porta, António Araújo, Aung Naing, David Hong, Shahanavaj Khan, Nele Van Der Steen, Peter Van Dam, Rafael Sirera, Andreia Coelho, Pablo Reclusa, Roberto Borea, Jose Ferri, Roberto Borea, Christian Rolfo

Risultato della ricerca: Articlepeer review

133 Citazioni (Scopus)


Introduction The Fibroblast Growth Factor Receptor (FGFR) family consists of Tyrosine Kinase Receptors (TKR) involved in several biological functions. Recently, alterations of FGFR have been reported to be important for progression and development of several cancers. In this setting, different studies are trying to evaluate the efficacy of different therapies targeting FGFR. Areas Covered This review summarizes the current status of treatments targeting FGFR, focusing on the trials that are evaluating the FGFR profile as inclusion criteria: Multi-Target, Pan-FGFR Inhibitors and anti-FGF (Fibroblast Growth Factor)/FGFR Monoclonal Antibodies. Expert opinion Most of the TKR share intracellular signaling pathways; therefore, cancer cells tend to overcome the inhibition of one tyrosine kinase receptor by activating another. The future of TKI (Tyrosine Kinase Inhibitor) therapy will potentially come from multi-targeted TKIs that target different TKR simultaneously. It is crucial to understand the interaction of the FGF-FGFR axis with other known driver TKRs. Based on this, it is possible to develop therapeutic strategies targeting multiple connected TKRs at once. One correct step in this direction is the reassessment of multi target inhibitors considering the FGFR status of the tumor. Another opportunity arises from assessing the use of FGFR TKI on patients harboring FGFR alterations.
Lingua originaleEnglish
pagine (da-a)256-267
Numero di pagine12
Stato di pubblicazionePublished - 2017

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2717???
  • ???subjectarea.asjc.2700.2720???
  • ???subjectarea.asjc.2700.2730???


Entra nei temi di ricerca di 'FGFR a promising druggable target in cancer: Molecular biology and new drugs'. Insieme formano una fingerprint unica.

Cita questo